Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Jonathan E. Rosenberg"'
Autor:
Min Yuen Teo, Brendan J. Guercio, Arshi Arora, Xueli Hao, Ashley M. Regazzi, Timothy Donahue, Harry W. Herr, Alvin C. Goh, Eugene K. Cha, Eugene Pietzak, Sherri M. Donat, Guido Dalbagni, Bernard H. Bochner, Semra Olgac, Judy Sarungbam, S. Joseph Sirintrapun, Ying-Bei Chen, Anuradha Gopalan, Samson W. Fine, Satish K. Tickoo, Victor E. Reuter, Britta Weigelt, Anne M. Schultheis, Samuel A. Funt, Dean F. Bajorin, David B. Solit, Gopa Iyer, Irina Ostrovnaya, Jonathan E. Rosenberg, Hikmat Al-Ahmadie
Publikováno v:
Clin Genitourin Cancer
INTRODUCTION: Small cell carcinoma of the bladder (SCCB) is a rare variant of bladder cancer with poor outcomes. We evaluated long-term outcomes of nonmetastatic (M0) and metastatic (M1) SCCB and correlated pathologic response with genomic alteration
Autor:
Joshua J. Meeks, Peter C. Black, Matthew Galsky, Petros Grivas, Noah M. Hahn, Syed A. Hussain, Matthew I. Milowsky, Gary D. Steinberg, Robert S. Svatek, Jonathan E. Rosenberg
Publikováno v:
European Urology.
Autor:
Andrew B. Katims, Andrew T. Lenis, Ronak H. Shah, Carissa E. Chu, Neha Ratna, Ashely M. Regazzi, Eugene J. Pietzak, David H. Aggen, Samuel A. Funt, Min Yuen Teo, Jonathan E. Rosenberg, Dean F. Bajorin, Timothy F. Donahue, Bernard H. Bochner, Michael F. Berger, David B. Solit, Gopa Iyer
Publikováno v:
Journal of Urology. 209
Autor:
Daniel P. Petrylak, Cindy Xu, Corina Andresen, Ulka N. Vaishampayan, Jessica Rearden, Howard A. Burris, Jean H. Hoffman-Censits, Ugo De Giorgi, Sumanta K. Pal, Sumati Gupta, Jonathan E. Rosenberg, Dean F. Bajorin, Yung Lyou, Ai Li, Siamak Daneshmand, David I. Quinn, Petros Grivas, Susan Moran, Matthew D. Galsky
Publikováno v:
Clinical Genitourinary Cancer. 20:35-42
Introduction To describe the efficacy of infigratinib, a potent, selective fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor, across lines of therapy (LOT) in patients with metastatic urothelial cancer (mUC). Patients and Methods
Autor:
Daniel P. Petrylak, Robert Dreicer, Sabine de Ducla, Michiel S. van der Heijden, Jens Bedke, Jonathan E. Rosenberg, Thomas Powles, Yohann Loriot, Jose Luis Perez-Gracia, Simon Fear, Ernest Choy, Lars Thiebach, Axel S. Merseburger, Ignacio Duran, Cora N. Sternberg, Julie Pavlova, Daniel Castellano, Jean H. Hoffman-Censits
Publikováno v:
European urology focus, 7(5), 1084-1091. Elsevier BV
Background The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilis
Autor:
Darren R. Feldman, Martin H. Voss, Ashley Marie Regazzi, Dana E. Rathkopf, Robert J. Motzer, Michael J. Morris, Gopa Iyer, Jonathan E. Rosenberg, Michal Sarfaty, Dean F. Bajorin
Publikováno v:
Clinical Genitourinary Cancer
Background The worldwide COVID-19 public health pandemic has restructured clinical care of cancer patients throughout the world. The specific changes in the management of genitourinary (GU) cancers in different cancer centers due to COVID-19 are not
Autor:
Vadim S. Koshkin, Bernadett Szabados, Daniel Castellano, Matthew D. Galsky, Petros Grivas, Lucia Carril-Ajuria, Min Y. Teo, Daniele Raggi, Guru Sonpavde, Parissa Alerasool, Thomas Powles, Lillian Werner, Jacob Gaines, Xiao X. Wei, Ravindran Kanesvaran, Joaquim Bellmunt, Jonathan E. Rosenberg, Andrea Necchi, Noah M. Hahn, Rana R. McKay, Laura Morrison, Pedro Isaacsson Velho
Publikováno v:
J Urol
PURPOSE: Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy. However, the optimal sequencin
Autor:
Dean F. Bajorin, Samuel A. Funt, Min Yuen Teo, Guido Dalbagni, David B. Solit, Eugene J. Pietzak, Jose Mauricio Mota, Hikmat Al-Ahmadie, Chung-Han Lee, Karissa Whiting, Han A. Li, Bernard H. Bochner, Gopa Iyer, Jonathan E. Rosenberg, Arjun Vasant Balar, Matthew I. Milowsky, Irina Ostrovnaya
Publikováno v:
European Urology. 78:907-915
Background Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). Objective To determine the association between FGFR3 status and response to
Publikováno v:
Nature Reviews Urology. 18:93-103
Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the most common type of bladder cancer and accounts for 90% of bladder cancer cases in the USA and Europe. Novel approaches are needed to improve patient outcomes.
Autor:
Lucas W. Dean, Timothy F. Donahue, Lorenzo Di Cesare Mannelli, Junting Zheng, Guido Dalbagni, Shawn Dason, Nathan C. Wong, Di Paolo Pl, M. Capeanu, Victor McPherson, H. A. Vargas, Andreas Meier, Bernard H. Bochner, Jonathan E. Rosenberg, Dean F. Bajorin
Publikováno v:
Journal of Urology. 204:254-259